SCHEMBL18649028

SCHEMBL18649028

CC(C)(C)c1cccc(S(=O)(=O)NCc2ccccc2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.63
LMNA P02545 3/20 0.57
SLC12A2 P55011 1/20 0.57
SLC12A5 Q9H2X9 1/20 0.57
HDAC2 Q92769 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
HTT P42858 1/20 0.56
CA12 O43570 2/20 0.55
CA9 Q16790 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
ATM Q13315 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
RAB9A P51151 2/20 0.54
CYP19A1 P11511 3/20 0.52
GLA P06280 1/20 0.52
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
PKM P14618 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13888909 0.91 KEAP1 (0.63) KEAP1LMNACA12CA9CYP1A2
SCHEMBL12982899 0.83 KEAP1 (0.69) KEAP1LMNAHDAC8HDAC6HTT
SCHEMBL14015272 0.82 KEAP1 (0.63) KEAP1LMNASLC12A2SLC12A5HDAC2
SCHEMBL10176295 0.81 KMT2A (0.47) LMNAHDAC8HDAC6HTTCA9
SCHEMBL16660687 0.80 ALDH1A1 (0.73) KEAP1LMNASLC12A2SLC12A5HDAC2
SCHEMBL10268297 0.80 KEAP1 (0.69) KEAP1LMNASLC12A2SLC12A5HDAC2
SCHEMBL12982562 0.80 POLB (0.53) ALDH1A1SMN1; SMN2PKM
SCHEMBL21726734 0.79 KMT2A (0.53) LMNAHDAC8HDAC6HTTCA12
SCHEMBL407414 0.79 KEAP1 (1.00) KEAP1LMNASLC12A2SLC12A5HDAC2
SCHEMBL14025561 0.78 KEAP1 (0.71) KEAP1LMNASLC12A2SLC12A5HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10941160-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-09 US disclosed
US-20200148703-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-05-14 US disclosed
US-10562915-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-02-18 US disclosed
US-10023592-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-17 US disclosed
US-20170158709-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2017-06-08 US disclosed
US-9598372-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2017-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158709-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 KEAP1 853/4885LMNA 1464/4885SLC12A2 4816/4885
US-10562915-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 KEAP1 853/4885LMNA 1464/4885SLC12A2 4816/4885
US-10023592-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 KEAP1 853/4885LMNA 1464/4885SLC12A2 4816/4885
US-10941160-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 KEAP1 853/4885LMNA 1464/4885SLC12A2 4816/4885
US-20200148703-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 KEAP1 853/4885LMNA 1464/4885SLC12A2 4816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.